NeuroPrecision Lab

NeuroPrecision Lab | @PittStroke | Advancing precision care for acute neurological disorders and driving innovation through clinical research and technology.

[NeuroPrecision Lab @NeuroprecisionL]

@RaulNogueiraMD delivered two platform presentations at the LINNC Paris—the most prestigious neuroendovascular conference!

[Mohamed F Doheim, MD, PhD @fahmy_doheim]

🚨Our stratified analysis published @JNNP_BMJ (4,548 stroke admissions) across 4 hubs + 60 spokes shows that an AI-driven triage platform improved workflow and increased EVT utilization with remarkable cost savings!
@PittStroke @PittNeurology
🔗 https://t.co/ey8RKj1nvA

[NeuroPrecision Lab @NeuroprecisionL]

An insightful presentation and discussion points by @RaulNogueiraMD on MeVOs and the art of trial design during NIH STEP webinar! @PittStroke @PittNeurology

[Mohamed F Doheim, MD, PhD @fahmy_doheim]

“Hospitals treat efficiently once patients arrive, yet many patients lose critical hours before they reach them”
Please read our editorial on ICH reversal and system of care fragmentation
🔗 https://t.co/LucvZFuvS6
Thanks for the invitation @OmarAlJanabiMD @Mo_majali91

[NeuroPrecision Lab @NeuroprecisionL]

A great win for our field with the presentation of ORIENTAL MeVO — the first trial on moderate to severe MeVO (median NIHSS=10). The study opens the door for future adaptive research. Presented by our own @RaulNogueiraMD at #ISC26.
@PittStroke

[Mohamed F Doheim, MD, PhD @fahmy_doheim]

Happy to present our DUSK tool to individualize treatment for distal medium vessel occlusion! Time to move beyond “one-size-fits-all”@PittStroke @PittNeurology @NeuroprecisionL

[Mohamed F Doheim, MD, PhD @fahmy_doheim]

Pleased to present our work on multidimensional clot characterization and the need for real time assessment and dynamic evaluation for optimizing first line technique and procedural outcomes! @PittStroke @PittNeurology @NeuroprecisionL

[Mohamed F Doheim, MD, PhD @fahmy_doheim]

From “Does EVT work for DMVO?”❌ to "WHICH patients benefit most?" ✅, we used explainable counterfactual model to move beyond "one-size-fits-all".🧐

🔗 https://t.co/uVvAus29qn

🔗 https://t.co/3akd7dSsvz

@ANA_journals @NeuroprecisionL @PittStroke @PittNeurology @RaulNogueiraMD

[NeuroPrecision Lab @NeuroprecisionL]

@RaulNogueiraMD presenting on “Intra-Arterial Nano-Thrombolysis in Stroke” at the Brain meeting in London.

[Mohamed F Doheim, MD, PhD @fahmy_doheim]

Happy to share two new co-authored multicenter publications on tenecteplase vs alteplase in BAO patients undergoing EVT, with contributions from @PittStroke and @NeuroprecisionL
🔗 https://t.co/8nOckHkDao
🔗 https://t.co/po7AmTZy3L

[NeuroPrecision Lab @NeuroprecisionL]

Contact aspiration’s first-pass benefits seemingly “offset” by inferior final recanalisation versus stent retrievers in basilar occlusion stroke
🔗 https://t.co/tSPOhrb8LG
@RaulNogueiraMD @PittStroke @PittNeurology

[NeuroPrecision Lab @NeuroprecisionL]

🚨 New from the VERITAS collaboration: Bridging IVT→EVT in basilar artery occlusion is safe but shows no added benefit vs EVT alone which establish equipoise. Findings from pooled 4 RCTs support tailored decision-making in VBAO strokes. @PittStroke
🔗 https://t.co/5MO2RK82xd

[World Stroke Academy @WorldStrokeEd]

#WSC2025

#IAT_TOP

🌐 Multicenter RCT 🇨🇳n=246
💉 IA-tPA 0.225 mg/kg vs standard care after eTICI ≥ 2b50 in posterior AIS

🎯 mRS 0–2 at 90d:
🟡41.9% vs 46.7% (NS)
⚠️ sICH ≈ 2.5%, no excess risk

➡️ No functional benefit of adjunct IA-tPA after EVT in PC stroke
@RaulNogueiraMD

[NeuroPrecision Lab @NeuroprecisionL]

Our @RaulNogueiraMD in Opening & Closing Plenaries! 🧠
1️⃣ #ANGEL_COAST: BAO<24h → ↑CA, ↑FPE, ↓complete recan, no clinical difference.
2️��� #IAT_TOP: mRS 0–2 @90d 41.9% vs 46.7% (NS) but safe.
3️⃣ HEMERA-1: #PP_007 shows promise vs matched @PittStroke @fahmy_doheim @PittNeurology

[NeuroPrecision Lab @NeuroprecisionL]

🧠PEARL RCT co-authored by @RaulNogueiraMD: IA alteplase after thrombectomy → better recovery (mRS 0-1: 45% vs 30%) w/o ↑ bleeding.
🔗https://t.co/1sYoaADHEe

✅ Matches our pooled analysis on IAT post-EVT.
🔗 https://t.co/xufjThn6Fa @fahmy_doheim @PittStroke
#NeuroTwitter